Skip to main content
micro-community-banner
 
  • Saved

made a Post

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report - PubMed

We report about SCCT that occurred 45 months after the initial diagnosis of ADC in an East Asian never-smoker woman with advanced-stage EGFR Del-19-mutant lung ADC treated with combined chemoradiotherapy ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33816221/

  • Saved

made a Post

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer - PubMed

Non─small cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. The homology between the tyrosine kinase domains ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33743408/

  • Saved

made a Post

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives - PubMed

The potent, RET-selective tyrosine kinase inhibitors (TKIs) pralsetinib and selpercatinib, are effective against the RET V804L/M gatekeeper mutants, however, adaptive mutations that cause resistance at the solvent front RET G810 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33806299/

  • Saved

made a Post

Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals - PubMed

The continued introduction of biomarkers and innovative testing methods makes already complex diagnosis in patients with stage IV non-small-cell lung cancer (NSCLC) even more complex. This study primarily analyzed variations ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33493663/

  • Saved

made a Post

Therapeutic strategies in RET gene rearranged non-small cell lung cancer - PubMed

The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches. RET gene ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33771190/

  • Saved

made a Post

Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy - PubMed

GLOBOCAN 2018 identified lung cancer as the leading oncological pathology in terms of incidence and mortality rates. Angiogenesis is a key adaptive mechanism of numerous malignancies that promotes metastatic spread ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33121202/

  • Saved

made a Post

NCCN Updates Clinical Practice Guideline for Small Cell Lung Cancer

On March 23, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for small cell lung cancer. The version 3.2021 update features modifications for ..... see more

Source : https://www.journalofclinicalpathways.com/news/nccn-updates-clinical-practice-guideline-small-cell-lung-cancer

  • Saved

made a Post

Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials

Lung cancer remains the leading cause of death among cancer patients worldwide, and approximately 85% of lung cancers are non-small cell lung cancer (NSCLC) ( 1). A series of clinical ..... see more

Source : https://apm.amegroups.com/article/view/61988/html

  • Saved

made a Post

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib - PubMed

Through the use of SPPs, we were able to offer combination therapy targeting MET -amplified resistance identified on the first-in-human study of selpercatinib. These data suggest that MET dependence is ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33082208/

  • Saved

made a Post

A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations - PubMed

doi: 10.4155/bio-2020-0199. Online ahead of print. 1 CHRU de Tours, Plateforme Recherche, Centre Pilote de Suivi Biologique des Traitements par Anticorps (CePiBAc), Tours, France. 2 Université de Tours, EA4245 Transplantation, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33769095/

  • Saved

made a Post

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Posit | CMAR

Francesco Facchinetti, 1, 2 Antonin Levy, 3, 4 Samy Ammari, 5 Charles Naltet, 6 Pernelle Lavaud, 6 Mihaela Aldea, 6 Damien Vasseur, 7 David Planchard, 6 Benjamin Besse 2, 6 ..... see more

Source : https://www.dovepress.com/meningeal-ldquolazarus-responserdquo-to-lorlatinib-in-a-ros1-positive--peer-reviewed-article-CMAR

  • Saved

made a Post

[Full text] Recognizing Prognostic and Predictive Biomarkers in the Treatment of N | LCTT

PD-L1 testing is done through IHC with different assays utilized with various PD-1 or PD-L1 inhibitors; the mechanism of action of these inhibitors in relation to PD-L1 is well described. ..... see more

Source : https://www.dovepress.com/recognizing-prognostic-and-predictive-biomarkers-in-the-treatment-of-n-peer-reviewed-fulltext-article-LCTT

  • Saved

made a Post

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma - PubMed

Lung cancer is one of the most common malignant neoplasms. As a result of the disease's progression, patients may develop metastases to the central nervous system. The prognosis in this ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33435596/

  • Saved

made a Post

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer-A Systematic Review and Network Meta-Analysis - PubMed

The efficacy and safety of immune checkpoint inhibitors (ICIs) in refractory or relapsed advanced non-small-cell lung cancer (NSCLC) have not yet been compared with those of ramucirumab (Ram) plus docetaxel ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33561074/

  • Saved

made a Post

A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Background Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison ..... see more

Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08005-1

57-Year-Old Never-Smoker with Dyspnea

Tom, a 57-year-old never-smoker, presented complaining of coughing, dyspnea, and fatigue. Other than mild hypertension controlled with losartan 100 mg, Tom has no ..... see more

Show More Comments

  • 2 weeks 6 days
    I would attempt a repeat biopsy or at least run a liquid biopsy to see if a resistance mutation can be identified, for example, if we identified G1202R mutation, Show More
  • 2 weeks 6 days
    pt with alk pos lung ca ,lorlatinib has marked brain penetration would consider lorlatinib ,though brigatinib and alcensa are other options
  • Saved

made a Post

LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer - PubMed

Lung cancer has a higher incidence rate and mortality rate than all other cancers. Early diagnosis and treatment of lung cancer remain a major challenge, and the 5-year survival rate ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33728331/

  • Saved

made a Post

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival benefit in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Measuring TMB in ..... see more

Source : https://clincancerres.aacrjournals.org/content/27/6/1631.abstract

  • Saved

made a Post

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy - PubMed

doi: 10.1136/jitc-2020-001966. 1 Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege, Liege, Belgium. 2 Laboratory of Immunophysiology, GIGA-I3, University of Liege, Liege, Belgium. 3 Faculty of Veterinary Medicine, University of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33712445/